Most children with R/R solid tumors experience multiple events and therapy regimens without a break. Presence of a >30-day break did not negatively affect survival, implying that time between therapy regimens can safely be offered to select patients to promote quality of life and thoughtful decision-making, without compromising survival.
McEvoy et al. (Sun,) studied this question.